International Urogynecology Journal

, Volume 19, Issue 11, pp 1545–1550 | Cite as

Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy

  • M. P. FitzGeraldEmail author
  • G. Lemack
  • T. Wheeler
  • H. J. Litman
  • for the Urinary Incontinence Treatment Network
Original Article


To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.


Lower urinary tract Nocturia Antimuscarinic therapy Behavioral therapy Urge incontinence 



Supported by cooperative agreements (U01 DK58225, U01 DK58229, U01 DK58234, U01 DK58231, U01 DK60379, U01 DK60380, U01 DK60393, U01 DK60395, U01 DK60397, and U01 DK60401) with the National Institute of Diabetes and Digestive and Kidney Diseases and by the National Institute of Child Health and Human Development and Office of Research in Women’s Health of the National Institutes of Health.

Conflicts of interest

MP FitzGerald has received research funding from and has provided consultation to Pfizer Inc and Astellas. Dr Lemack is lecturer for Astellas, Allergan, Pfizer, Novartis, and Indevus, has received research funding from Allergan, and has provided consultation to Allergan, Pfizer, and Novartis.


  1. 1.
    van Kerrerebroeck PAP, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183CrossRefGoogle Scholar
  2. 2.
    Asplund R, Aberg HE (2000) Nocturia and health in women aged 40–64 years. Maturitas 35:143–148PubMedCrossRefGoogle Scholar
  3. 3.
    FitzGerald MP, Litman HJ, Link CL, McKinlay JB, for the BACH Survey Investigators (2007) The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the Boston Area Community Health (BACH) survey. J Urol 177:1385–1389PubMedCrossRefGoogle Scholar
  4. 4.
    Coyne KS, Zhou Z, Battacharyya SK, Thompson CL, Dhawan R, Versi E (2003) The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92:948PubMedCrossRefGoogle Scholar
  5. 5.
    Asplund R, Aberg H (1992) Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 10:98–104PubMedCrossRefGoogle Scholar
  6. 6.
    van Balen RSE, Polder JJ et al (2001) Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthopsedics and Relat Res 390:232–243CrossRefGoogle Scholar
  7. 7.
    Asplund R (2006) Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriatr 43:319–326PubMedCrossRefGoogle Scholar
  8. 8.
    Asplund R (2007) Pharmacotherapy for nocturia in the elderly patient. Drugs Aging 24:325–343PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson TM, Burgio KL, Reden DT, Wright KC, Goode PS (2005) Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 53:846–850PubMedCrossRefGoogle Scholar
  10. 10.
    The Urinary Incontinence Treatment Network (2007) Design of the behavior enhances drug reduction of incontinence (BE-DRI) study. Contemporary Clinical Trials 28:48–58CrossRefGoogle Scholar
  11. 11.
    Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager C, Kenton K, Tennstedt SL, Kusek JW, Chang TD, Nyberg LM, Steers W for the Urinary Incontinence Treatment Network. (2008) Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 149:161–169Google Scholar
  12. 12.
    Diokno AC, Brock BM, Brown MB, Herzog AR (1986) Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol 136:1022–1025PubMedGoogle Scholar
  13. 13.
    Lowenstein L, Brubaker L, Kenton K, Kramer H, Shott S, FitzGerald MP (2007) Prevalence and impact of nocturia in a urogynecologic population. Int Urogynecol J 18:1049–1052CrossRefGoogle Scholar
  14. 14.
    Weiss JP, Blaivas JG, Jones M, Wang JT, Guan Z, 037 Study Group (2007) Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 178:548–551PubMedCrossRefGoogle Scholar
  15. 15.
    Brubaker L, FitzGerald MP (2007) Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogyn J 18:737–741CrossRefGoogle Scholar
  16. 16.
    Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, 037 Study Group (2006) Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67:731–736PubMedCrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2008

Authors and Affiliations

  • M. P. FitzGerald
    • 1
    • 5
    Email author
  • G. Lemack
    • 2
  • T. Wheeler
    • 3
  • H. J. Litman
    • 4
  • for the Urinary Incontinence Treatment Network
  1. 1.Loyola University Medical CenterMaywoodUSA
  2. 2.University of Texas Southwestern Medical CenterDallasUSA
  3. 3.University of Alabama Medical CenterBirminghamUSA
  4. 4.New England Research InstitutesWatertownUSA
  5. 5.Division of Female Pelvic Medicine and Reconstructive SurgeryLoyola University Medical CenterMaywoodUSA

Personalised recommendations